-
Inhibikase Q2 net loss widens to $19.6M; Phase 3 PAH trial advances with $50M financing
Q2 2026 net loss $19.6M ($0.11/share) vs $9.9M loss in Q2 2025; R&D spend up to $13.4M from $5.3M.
-
Inhibikase Therapeutics exchanges 18M shares with RA Capital for pre-funded warrants
RA Capital exchanged 18,030,000 common shares for pre-funded warrants with $0.001 exercise price.
-
Inhibikase Therapeutics receives FDA Orphan Drug Designation for IKT-001 in PAH
FDA granted Orphan Drug Designation to IKT-001 (prodrug of imatinib mesylate) for Pulmonary Arterial Hypertension.
-
Inhibikase raises $50M through ATM sale of 25M shares to RA Capital for PAH study
Sold 25,000,000 shares to RA Capital Management for $50M gross proceeds via ATM facility.
-
Inhibikase Q1 2026 net loss $16.4M; first patient enrolled in Phase 3 PAH study IMPROVE-PAH
Net loss $16.4M ($0.10 EPS) vs $13.7M ($0.15) in Q1 2025; cash & equivalents $170.4M as of Mar 31, 2026.
-
Inhibikase enrolls first patient in Phase 3 PAH study of IKT-001
First patient enrolled in global pivotal Phase 3 IMPROVE-PAH trial (NCT07365332).
-
Inhibikase reports FY2025 net loss $48.3M; advances IKT-001 into Phase 3 PAH trial
Net loss of $48.3M ($0.49/share) for FY2025 vs $27.5M ($1.16/share) in FY2024.
-
Inhibikase raises ~$93.6M in public offering, advances IKT-001 to Phase 3 PAH trial
Offering of 46.1M shares at $1.45/share and pre-funded warrants for 22.9M shares; net proceeds ~$93.6M.
-
IKT advances IKT-001 to global pivotal Phase 3 in PAH; ATM prospectus terminated
IMPROVE-PAH Phase 3 trial for IKT-001 in pulmonary arterial hypertension expected to start Q1 2026 across up to 180 sites.
-
Inhibikase Q3 net loss $11.9M ($0.13/sh); advancing IKT-001 Ph2b in PAH
Net loss $11.9M for Q3 2025 vs $5.8M YoY; cash $77.3M at Sep 30, down from $97.5M at Dec 2024.
-
Inhibikase Q2 net loss $9.9M; Phase 2b IKT-001 PAH trial to start H2 2025
Cash and marketable securities $87.7M at June 30, 2025, vs $97.5M at Dec 31, 2024.
-
Inhibikase Q1 net loss $13.7M; advancing IKT-001 PAH Ph2b trial in H2 2025
Net loss $13.7M ($0.15/share) vs $4.6M ($0.73) in Q1 2024; includes $7.4M non-cash acquisition charge for CorHepta.
-
Inhibikase Therapeutics appoints David McIntyre as CFO as Garth Lees-Rolfe resigns
Garth Lees-Rolfe resigned as CFO effective April 11, 2025; not due to any dispute with the Company.
-
Inhibikase reports 2024 net loss $27.5M; cash $97.5M; PAH trial progress, new leadership
Net loss $27.5M ($1.16 per share) vs $19.1M ($3.16 per share) in 2023; R&D $17.2M, SG&A $11.4M.
-
Inhibikase acquires CorHepta for $15M in stock; appoints Cabell as President and Adams as CSO
Acquired CorHepta for $15M in stock: 4,979,101 shares issued (3,319,397 upfront, remainder contingent on milestone).
-
Inhibikase appoints Mark Iwicki as CEO; founder Milton Werner resigns
Milton Werner resigned as CEO/board member effective Feb 13, 2025; will consult through May 13, 2025 at $44,583/month.
-
Inhibikase Phase 2 risvodetinib trial misses primary efficacy endpoint; development paused
Trial enrolled 126 untreated Parkinson's patients; 95% completed 12 weeks with safety comparable to placebo.
-
Inhibikase shareholders approve 5x authorized share increase to 500M and option repricing
Stockholders approved increase in authorized common shares from 100M to 500M; Certificate of Amendment filed Jan 3, 2025.
-
Inhibikase closes $110M private placement, up to $275M total, advances IkT-001Pro in PAH
Gross proceeds ~$110M from private placement; potential aggregate up to ~$275M from warrant exercises.
-
Inhibikase raises ~$110M in private placement; appoints four new directors
Gross proceeds ~$110M from common stock, pre-funded warrants, and Series A-1/B-1 warrants at $1.37 per share unit.
-
Inhibikase raises $4.0M in registered direct offering and warrant inducement
Offering of 1,672,452 shares (or pre-funded warrants) at $1.68/unit with Series A and B warrants.
-
Inhibikase receives arbitration demand for $1.625M from Pivot over milestone payments
Pivot Holding LLC, successor to Sphaera Pharma, demands $1.625 million plus interest for alleged breach of 2012 collaboration agreement.
-
Inhibikase 201 trial ~75% enrolled; expects completion by mid-June 2024
201 Trial (risvodetinib) ~75% enrolled, 30 patients left; enrollment completion expected mid-June 2024.
-
Inhibikase receives FDA guidance on 505(b)(2) path for IkT-001Pro; Parkinson's trial enrolling 51 patients
FDA pre-NDA meeting on Jan 19, 2024: acknowledges 505(b)(2) pathway appropriate for IkT-001Pro in blood/gastrointestinal cancers.
-
Inhibikase CFO Joseph Frattaroli to retire; Garth Lees-Rolfe promoted as successor
Joseph Frattaroli to retire as CFO effective March 31, 2024; vested stock option exercise period extended.
-
Inhibikase provides pipeline updates after sharp stock decline; 201 Trial enrollment at 28 patients
Stock dropped dramatically over last 8 trading sessions; no identifiable cause for volatility.
-
Inhibikase Therapeutics announces 1-for-6 reverse stock split to regain Nasdaq compliance
Reverse stock split effective June 30, 2023; shares outstanding reduced from ~31.6M to ~5.3M.
-
Inhibikase raises ~$10M via registered direct offering and private placement with warrants
Offering includes 6,744,187 shares/equivalents at $0.86/share in registered direct, plus 4,883,721 in private placement.
-
FDA lifts full clinical hold on Inhibikase's IkT-148009 for Parkinson's; Phase 2a trial restarting
FDA lifted full clinical hold on IkT-148009; Phase 2a 201 trial resumes at 50 and 100 mg doses.
-
Inhibikase Q3 net loss $4.49M; FDA clinical hold on IkT-148009 programs
Q3 2022 net loss of $4.49M ($0.18 per share) vs. $4.47M in Q3 2021.
-
FDA imposes clinical hold on Inhibikase's IkT-148009 Parkinson's and MSA programs
FDA placed a clinical hold on the IkT-148009 201 program in Parkinson's disease and its use in Multiple Systems Atrophy (MSA).
-
Inhibikase Therapeutics presents Phase 1/1b data for IkT-148009 in Parkinson's; Phase 2 ongoing
Phase 1/1b of IkT-148009 (88 healthy, 13 PD patients) showed no clinically significant AEs, linear PK, and CNS penetration over 12.5-325 mg daily doses.